SV1999000141A - Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb - Google Patents

Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb

Info

Publication number
SV1999000141A
SV1999000141A SV1999000141A SV1999000141A SV1999000141A SV 1999000141 A SV1999000141 A SV 1999000141A SV 1999000141 A SV1999000141 A SV 1999000141A SV 1999000141 A SV1999000141 A SV 1999000141A SV 1999000141 A SV1999000141 A SV 1999000141A
Authority
SV
El Salvador
Prior art keywords
formula
ona
quinolin
derivatives
cancer agents
Prior art date
Application number
SV1999000141A
Other languages
English (en)
Inventor
Greca Susan Deborah La
Joseph Peter Lyssikatos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV1999000141A publication Critical patent/SV1999000141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FORMULA 1, (VER FORMULA); Y A SALES, PROFÁRMACOS Y SOLVATOS FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, FORMULA EN LA QUE R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 Y R11, FORMULA EN LA QUE R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 Y R11 SON COMO SE HAN DEFINIDO ANTERIORMENTE. LOS COMPUESTOS DE FORMULA 1 SON ÚTILES EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS, COMO CÁNCERES, EN MAMÍFEROS. LA INVENCIÓN SE REFIERE TAMBIÉN A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS DE FORMULA 1 Y A PROCEDIMIENTOS PARA INHIBIR EL DESARROLLO ANORMAL DE CELULAS, INCLUIDOS CÁNCERES, EN UN MAMÍFERO ADMINISTRANDO LOS COMPUESTOS DE FORMULA 1 A UN MAMÍFERO QUE REQUIERA DICHO TRATAMIENTO
SV1999000141A 1998-08-27 1999-08-27 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb SV1999000141A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9814598P 1998-08-27 1998-08-27

Publications (1)

Publication Number Publication Date
SV1999000141A true SV1999000141A (es) 2000-07-06

Family

ID=22267481

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000141A SV1999000141A (es) 1998-08-27 1999-08-27 Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb

Country Status (40)

Country Link
US (3) US6150377A (es)
EP (1) EP1107963B1 (es)
JP (1) JP3495706B2 (es)
KR (1) KR20010072991A (es)
CN (1) CN1314904A (es)
AP (1) AP2001002079A0 (es)
AT (1) ATE321037T1 (es)
AU (1) AU4925499A (es)
BG (1) BG105365A (es)
BR (1) BRPI9913138B8 (es)
CA (2) CA2341690C (es)
CO (1) CO5130017A1 (es)
CZ (1) CZ2001660A3 (es)
DE (1) DE69930518T2 (es)
DZ (1) DZ2880A1 (es)
EA (1) EA200100135A1 (es)
EE (1) EE200100118A (es)
ES (1) ES2259237T3 (es)
GE (1) GEP20033001B (es)
GT (1) GT199900140A (es)
HK (1) HK1039123A1 (es)
HR (1) HRP20010142A2 (es)
HU (1) HUP0103228A3 (es)
ID (1) ID27562A (es)
IL (1) IL141239A0 (es)
IS (1) IS5818A (es)
MA (1) MA26680A1 (es)
NO (1) NO20010964L (es)
NZ (1) NZ509372A (es)
OA (1) OA11645A (es)
PA (1) PA8480101A1 (es)
PE (1) PE20000986A1 (es)
PL (1) PL346426A1 (es)
SK (1) SK2442001A3 (es)
SV (1) SV1999000141A (es)
TN (1) TNSN99162A1 (es)
TR (1) TR200101343T2 (es)
UY (1) UY25682A1 (es)
WO (1) WO2000012499A1 (es)
ZA (1) ZA200101173B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
UA64797C2 (uk) * 1998-07-06 2004-03-15 Янссен Фармацевтика Н.В. Інгібітори фарнезил білок трансферази як засіб для лікування артропатії
ID27562A (id) * 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ATE289602T1 (de) * 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
ID29584A (id) 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
ES2313991T3 (es) * 2000-09-25 2009-03-16 Janssen Pharmaceutica Nv Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
CA2632091C (en) 2000-12-19 2011-03-22 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
US7129356B2 (en) 2000-12-27 2006-10-31 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002253101B2 (en) * 2001-03-12 2007-08-09 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
WO2002098425A1 (en) * 2001-06-04 2002-12-12 Cytovia, Inc. Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
WO2003080058A1 (en) 2002-03-22 2003-10-02 Janssen Pharmaceutica. N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
CA2510850A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
EP1691812A4 (en) 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
UA87153C2 (ru) * 2004-08-26 2009-06-25 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
AU2005276132B2 (en) * 2004-08-26 2011-09-29 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ME01509B (me) 2004-11-05 2014-04-20 Janssen Pharmaceutica Nv Terapeutska upotreba inhibitora farneziltransferaze i postupci praćenja njihove efikasnosti
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
PT2447283E (pt) 2005-09-07 2015-10-08 Pfizer Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
US8062838B2 (en) 2005-09-20 2011-11-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP5089681B2 (ja) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
EP2016074B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007251282A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
BRPI0715829A2 (pt) 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
WO2008112525A2 (en) * 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en) 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
JP6630742B2 (ja) 2015-08-17 2020-01-15 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
CN108601752A (zh) 2015-12-03 2018-09-28 安吉奥斯医药品有限公司 用于治疗mtap缺失型癌症的mat2a抑制剂
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
CN109999037A (zh) 2017-02-21 2019-07-12 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW201919628A (zh) 2017-08-07 2019-06-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20220002396A1 (en) 2018-11-01 2022-01-06 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020132437A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2020205486A1 (en) 2019-03-29 2020-10-08 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
ID27562A (id) * 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker

Also Published As

Publication number Publication date
CA2341690C (en) 2007-04-17
IS5818A (is) 2001-01-19
TNSN99162A1 (fr) 2005-11-10
CO5130017A1 (es) 2002-02-27
EA200100135A1 (ru) 2001-08-27
ID27562A (id) 2001-04-12
ATE321037T1 (de) 2006-04-15
CZ2001660A3 (cs) 2002-05-15
BR9913138A (pt) 2001-05-08
DE69930518T2 (de) 2006-09-21
DZ2880A1 (fr) 2003-12-15
MA26680A1 (fr) 2004-12-20
BRPI9913138B8 (pt) 2016-05-17
HUP0103228A2 (hu) 2002-02-28
JP2002523504A (ja) 2002-07-30
TR200101343T2 (tr) 2001-09-21
US6150377A (en) 2000-11-21
ES2259237T3 (es) 2006-09-16
UY25682A1 (es) 2000-03-31
GT199900140A (es) 2001-02-14
PL346426A1 (en) 2002-02-11
EE200100118A (et) 2002-06-17
HRP20010142A2 (en) 2002-02-28
CN1314904A (zh) 2001-09-26
DE69930518D1 (de) 2006-05-11
PA8480101A1 (es) 2003-06-30
CA2578326C (en) 2009-11-24
NO20010964L (no) 2001-04-26
HK1039123A1 (zh) 2002-04-12
EP1107963A1 (en) 2001-06-20
CA2341690A1 (en) 2000-03-09
US20020128287A1 (en) 2002-09-12
PE20000986A1 (es) 2000-09-30
BG105365A (en) 2001-11-30
EP1107963B1 (en) 2006-03-22
AU4925499A (en) 2000-03-21
CA2578326A1 (en) 2000-03-09
BR9913138B1 (pt) 2013-11-05
KR20010072991A (ko) 2001-07-31
US6294552B1 (en) 2001-09-25
US6579887B2 (en) 2003-06-17
IL141239A0 (en) 2002-03-10
HUP0103228A3 (en) 2003-01-28
SK2442001A3 (en) 2002-10-08
GEP20033001B (en) 2003-06-25
WO2000012499A1 (en) 2000-03-09
JP3495706B2 (ja) 2004-02-09
NO20010964D0 (no) 2001-02-26
ZA200101173B (en) 2002-04-12
NZ509372A (en) 2003-08-29
OA11645A (en) 2004-11-16
AP2001002079A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
SV1999000141A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
ATE289602T1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200102136T2 (tr) Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler.
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
SV1999000147A (es) Derivados de 4, 4-biarilpiperidina ref. pc10083/82759/bb
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
SV1999000251A (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina ref. pcl0085/82805/bb
CA2280905A1 (en) Highly lipophilic camptothecin derivatives
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
ECSP993118A (es) Derivados de quinolin -2 -ona alquinilsustituidos utiles como agentes anticancerosos
ECSP993117A (es) Derivados de quinolin -2 - ona utiles como agentes contra el cancer
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos
SV2002000474A (es) Derivados de higromicina a ref.pc11o32abcz/bb
ECSP003793A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY26460A1 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos.
ECSP982737A (es) Derivados de la tienopirimidina y de la tienopiridina como agentes anticancerigenos

Legal Events

Date Code Title Description
FD Lapse